| Methods |
Multicenter trial in Sweden.
Clinicians and participants were blinded.
4‐week washout period for acne treatments.
6 treatment cycles. |
| Participants |
160 healthy women over 15 years of age with at least 8 lesions on the face. Excluded women with contraindications to COCs. |
| Interventions |
Group 1: CPA 2 mg plus EE 35 µg
Group 2: CPA 2 mg plus EE 50 µg
Group 3: Levonorgestrel (LNG) 150 µg plus EE 30 µg |
| Outcomes |
Acne lesion counts.
Gynecologist, dermatologist and participant assessment of acne ("good," "moderate" or "poor").
Early discontinuation due to side effects. |
| Notes |
Randomization by manufacturer. No information on allocation concealment. Blinding with numbered packages. 35 women were excluded, discontinued early, were lost to follow up or were missing data. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
No information |
